Reviewer's report

**Title:** Targeting of CD34+CD38- cells using Gemtuzumab Ozogamicin (Mylotarg) in combination with Tipifarnib (Zarnestra) in Acute Myeloid Leukaemia

**Version:** 2  **Date:** 19 September 2012

**Reviewer:** Jörg Cammenga

**Reviewer's report:**

The author's have addressed all the issues and I have no further comments.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.